Saudi Arabia’s Voluntary Carbon Market Fuels the Shift to a Low-Carbon
Under UAE President’s directives, UAE launches urgent relief response for Ghana flood victims
Combating Desertification and Drought: Qatar a Model in Preserving Natural Resources, Establishing Environmental Stability
UAE allocates US$30 million for emergency humanitarian response in El Obeid, calls for civilian protection, safe humanitarian aid access in Sudan
Amman, Aug. 19 (Petra) U.S. pharmaceutical companies Merck and
Moderna announced Wednesday positive results from the final stage of
clinical trials for their experimental messenger RNA (mRNA) skin
cancer vaccine, intended for patients with advanced melanoma.
According to Agence France-Presse, the joint statement marks the
first time positive Phase 3 clinical trial results have been
disclosed for an mRNA-based cancer therapy.
The individualized therapy, known as intismeran autogene, was
administered alongside Merck’s immunotherapy drug Keytruda. The
combination yielded a statistically significant improvement in
recurrence-free survival among high-risk melanoma patients following
surgical resection, compared with Keytruda monotherapy.
Intismeran autogene uses mRNA technology to instruct cells to produce
proteins that trigger a targeted immune response. Custom-built for
each patient using specific mutations identified within their tumor,
the vaccine trains and activates the immune system to recognize and
attack cancer cells.
//Petra// AF
